Catalyst Wire Dossier Catalyst Wire Dossier

Emtricitabine/Rilpivirine/Tenofovir Alafenamide

emtricitabine/rilpivirine/tenofovir alafenamide
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Emtricitabine/Rilpivirine/Tenofovir Alafenamide, covering 2018-10-09 to 2018-10-09. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment [Phase 3]

See pricing